Full text is available at the source.
REAL-WORLD ASSOCIATIONS BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND DIABETIC RETINOPATHY ACCOUNTING FOR LONGITUDINAL GLYCEMIC CONTROL
Links Between Using GLP-1 Drugs and Diabetic Eye Disease Considering Blood Sugar Control Over Time
AI simplified
Abstract
GLP-1 RA use was associated with a reduced risk of diabetic retinopathy, diabetic macular edema, and treatment-requiring conditions over 10 years.
- Users of GLP-1 RAs had a 69% lower risk of developing diabetic retinopathy compared to non-users.
- There was a 60% reduction in the risk of diabetic macular edema among those using GLP-1 RAs.
- The risk of requiring treatment for diabetic retinopathy or diabetic macular edema was reduced by 82% in GLP-1 RA users.
- The findings suggest that GLP-1 RAs may offer protective benefits against serious eye complications in diabetes.
AI simplified